- 作者：Tomoko Ozawa ; Javed Afzal ; Kathleen R. Lamborn ; Andrew W. Bollen ; William F. Bauer ; Myoung-Seo Koo ; Stephen B. Kahl and Dennis F. Deen
- 刊名：International Journal of Radiation Oncology*Biology*Physics
- 出版年：2005
- 期刊代码：136_03603016
- 类别：med
- 出版时间：2005
- 卷：63
- 期：1
- 页码：247-252
- 文件大小：212 K
Methods and Materials: For the toxicity study, Fischer 344 rats were injected with graded concentrations of BOPP (35–100 mg/kg) into the tail vein. For boron biodistribution studies, 9L tumor-bearing rats received BOPP either systematically (intravenously) or locally.
Results: All rats that received 70 mg/kg BOPP and 70%of rats that received ≤60 mg/kg BOPP i.v. either had to be euthanized or died within 4 days of injection. In the biodistribution study, boron levels were relatively high in liver, kidney, spleen, and adrenal gland tissue, and moderate levels were found in all other organs. The maximum tumor boron concentration was 21.4 μg/g at 48 h after i.v. injection; this concentration of boron in brain tumors is at the low end of the range considered optimal for therapy. In addition, the tumor/blood ratio (approximately 1.2) was not optimal. When BOPP was delivered directly into intracerebral 9L tumors with CED, we obtained tumor boron concentrations much greater than those obtained by i.v. injection. Convection-enhanced delivery of 1.5 mg BOPP produced an average tumor boron level of 519 μg/g and a tumor/blood ratio of approximately 1850:1.
Conclusions: Our study demonstrates that changing the method of BOPP delivery from i.v. to CED significantly enhances the boron concentration in tumors and produces very favorable tumor/brain and tumor/blood ratios.